X4 Pharmaceuticals
(NASDAQ) XFOR
X4 Pharmaceuticals Financials at a Glance
Market Cap
$363.13M
Revenue (TTM)
$9.01M
Net Income (TTM)
-$99.72M
EPS (TTM)
-$4.54
P/E Ratio
-0.85
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Price
$3.76
Volume
399,540.951
Open
$3.84
Price
$3.76
Volume
399,540.951
Open
$3.84
Previous Close
$3.85
Daily Range
$3.72 - $4.00
52-Week Range
$1.35 - $4.83
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Price
$3.76
Volume
399,540.951
Open
$3.84
Previous Close
$3.85
Daily Range
$3.72 - $4.00
52-Week Range
$1.35 - $4.83
Estimated Earnings Date
Aug 6, 2026
XFOR News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout X4 Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
45
CEO
Adam R. Craig, MD, PhD
Website
www.x4pharma.comHeadquarters
Boston, MA 02134, US
XFOR Financials
Key Financial Metrics (TTM)
Gross Margin
79%
Operating Margin
-11%
Net Income Margin
-11%
Return on Equity
-104%
Return on Capital
-40%
Return on Assets
-37%
Earnings Yield
-1.18%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$363.13M
Shares Outstanding
94.32M
Volume
399.54K
Avg. Volume
421.08K
Financials (TTM)
Gross Profit
$28.86M
Operating Income
-$86.88M
EBITDA
-$85.61M
Operating Cash Flow
-$85.62M
Capital Expenditure
-$3.00M
Free Cash Flow
-$88.62M
Cash & ST Invst.
$253.00M
Total Debt
$77.29M
X4 Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.71M
-90.6%
Gross Profit
$2.11M
-91.1%
Gross Margin
77.92%
N/A
Market Cap
$363.13M
N/A
Market Cap/Employee
$2.54M
N/A
Employees
143
N/A
Net Income
-$20.24M
-7277.7%
EBITDA
-$20.07M
-124.1%
Quarterly Fundamentals
Total Cash
$233.72M
+168.8%
Total Debt
$733.00K
-99.1%
Accounts Receivable
$1.11M
-5.2%
Inventory
$4.64M
+50.1%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$733.00K
-43.7%
Return on Assets
-36.90%
N/A
Return on Invested Capital
-39.65%
N/A
Free Cash Flow
$0.00
+100.0%
Operating Cash Flow
-$19.60M
-58.5%